statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Equities researchers at Wedbush decreased their FY2024 EPS estimates for shares of Kiniksa Pharmaceuticals in a research report issued to...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to Post FY2024 Earnings of ($0.67) Per Share, Wedbush Forecasts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush decreased their FY2027 earnings per share (EPS) estimates for shares of Kiniksa Pharmaceuticals in a...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to Post FY2027 Earnings of $0.15 Per Share, Wedbush Forecasts

Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity Abiprubart development...

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Goldman Sachs analyst Paul Choi maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA Research Report) today. The company's shares opened toda...

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Goldman Sachs

This is a signal that KNSA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Kiniksa Pharmaceuticals (KNSA, $19.99) Stochastic Oscillator left the oversold zone on March 15, 2024

This indicator may be signaling that KNSA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Kiniksa Pharmaceuticals (KNSA, $20.36) entered Downtrend as Momentum indicator drops below 0 level on Mar 14, 2024

Over the last three days, A.I.dvisor has detected that KNSA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Kiniksa Pharmaceuticals (KNSA, $20.46) Aroon Indicator entered an Uptrend on March 13, 2024.

Kiniksa Pharmaceuticals (KNSA, $20.44) entered Downtrend as Momentum indicator drops below 0 level on Mar 12, 2024

Kiniksa Pharmaceuticals (KNSA, $20.44) Aroon Indicator entered an Uptrend on March 12, 2024.

Kiniksa Pharmaceuticals (KNSA, $20.34) Aroon Indicator entered an Uptrend on March 11, 2024.

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Volume	193,213.00
52-Wk High	$22.09
52-Wk Low	$10.65

KNSA Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals